CMV-MVA Triplex Vaccine to Enhance Adaptive NK Cell Reconstitution After Autologous Hematopoietic Cell Transplantation in Patients With Lymphoid Malignancies

Trial Profile

CMV-MVA Triplex Vaccine to Enhance Adaptive NK Cell Reconstitution After Autologous Hematopoietic Cell Transplantation in Patients With Lymphoid Malignancies

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 10 Apr 2018

At a glance

  • Drugs MVA CMV (Primary)
  • Indications Cytomegalovirus infections
  • Focus Pharmacodynamics
  • Most Recent Events

    • 10 Apr 2018 Planned End Date changed from 1 Jan 2020 to 1 Mar 2020.
    • 10 Apr 2018 Planned primary completion date changed from 1 Jan 2020 to 1 Mar 2020.
    • 10 Apr 2018 Planned initiation date changed from 1 Mar 2018 to 1 May 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top